Guido I. Marcucci
#124,526
Most Influential Person Now
Guido I. Marcucci's AcademicInfluence.com Rankings
Guido I. Marcucciphilosophy Degrees
Philosophy
#5784
World Rank
#8682
Historical Rank
Logic
#3000
World Rank
#4091
Historical Rank
Guido I. Marcuccibiology Degrees
Biology
#7785
World Rank
#10755
Historical Rank
Genetics
#753
World Rank
#845
Historical Rank
Molecular Biology
#925
World Rank
#948
Historical Rank
Download Badge
Philosophy Biology
Guido I. Marcucci's Degrees
- Doctorate Medicine University of California, San Francisco
Why Is Guido I. Marcucci Influential?
(Suggest an Edit or Addition)Guido I. Marcucci's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B (2007) (1603)
- Targeting microRNAs in cancer: rationale, strategies and challenges (2010) (1423)
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation (2017) (1382)
- Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. (2014) (1029)
- MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. (2009) (751)
- IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. (2010) (720)
- MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. (2008) (664)
- R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling (2018) (624)
- METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification. (2017) (612)
- Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? (2007) (584)
- Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. (2011) (564)
- miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts (2010) (555)
- Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. (2014) (513)
- Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. (2006) (508)
- The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. (2005) (501)
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine (2010) (458)
- MicroRNA expression in cytogenetically normal acute myeloid leukemia. (2008) (454)
- MicroRNA 29b functions in acute myeloid leukemia. (2009) (447)
- A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. (2004) (402)
- Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. (2012) (386)
- Prevention and treatment of cancer-related infections. (2012) (369)
- MicroRNA fingerprints during human megakaryocytopoiesis. (2006) (367)
- An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. (2008) (363)
- Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (363)
- FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. (2007) (349)
- Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. (2005) (335)
- Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. (2010) (333)
- Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. (2008) (326)
- TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. (2011) (324)
- Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. (2007) (310)
- Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics (2015) (304)
- FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. (2008) (287)
- Curcumin is a potent DNA hypomethylation agent. (2009) (286)
- High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. (2017) (281)
- Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. (2020) (279)
- ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. (2011) (270)
- Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. (2019) (267)
- The prognostic and functional role of microRNAs in acute myeloid leukemia. (2011) (266)
- Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. (2008) (266)
- Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion (2017) (263)
- BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. (2003) (250)
- Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. (2005) (249)
- NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. (2011) (248)
- RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. (2012) (247)
- Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. (1998) (243)
- A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. (2019) (239)
- Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. (2010) (233)
- CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. (2010) (229)
- The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia. (1998) (226)
- Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. (2006) (225)
- FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. (2010) (220)
- Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. (2003) (215)
- High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. (2007) (207)
- Expression and prognostic impact of lncRNAs in acute myeloid leukemia (2014) (205)
- Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia (2005) (203)
- Deregulation of DUX4 and ERG in acute lymphoblastic leukemia (2016) (197)
- Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. (2012) (194)
- PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. (2013) (193)
- Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. (2010) (191)
- High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. (2008) (190)
- Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. (2012) (190)
- A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. (2006) (188)
- Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia (2016) (181)
- Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. (2013) (179)
- Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia (2018) (173)
- Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. (2003) (172)
- Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. (2012) (168)
- Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. (2008) (163)
- Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. (2009) (162)
- Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay (1998) (160)
- Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia (2013) (155)
- RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia. (2020) (155)
- The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results (2019) (149)
- Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. (2008) (146)
- Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. (2012) (144)
- Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. (2005) (143)
- Estrogen Mediated-Activation of miR-191/425 Cluster Modulates Tumorigenicity of Breast Cancer Cells Depending on Estrogen Receptor Status (2013) (142)
- Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. (2005) (142)
- The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. (2005) (142)
- Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. (2013) (141)
- Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. (2013) (141)
- Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. (2008) (140)
- Leukocytoreduction for acute leukemia. (2002) (139)
- Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. (2008) (139)
- Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. (2006) (136)
- Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics (2005) (136)
- Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. (2014) (136)
- Acute myeloid leukemia, version 2.2013 featured updates to the NCCN guidelines (2013) (135)
- Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. (2006) (134)
- miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eµ-miR-155 transgenic mouse model (2012) (132)
- Bioavailability of Azacitidine Subcutaneous Versus Intravenous in Patients With the Myelodysplastic Syndromes (2005) (131)
- Leukemia-associated Rho Guanine Nucleotide Exchange Factor, a Dbl Family Protein Found Mutated in Leukemia, Causes Transformation by Activation of RhoA* (2001) (130)
- Regulation of acute graft-versus-host disease by microRNA-155. (2010) (129)
- Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. (2012) (128)
- Modulation of DNA Methylation by a Sesquiterpene Lactone Parthenolide (2009) (127)
- In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation (2013) (124)
- Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. (2001) (122)
- Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. (2013) (122)
- Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia (2017) (116)
- NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. (2021) (114)
- Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. (2011) (114)
- Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. (2014) (114)
- BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. (2010) (113)
- Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. (2008) (113)
- Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. (2012) (112)
- P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. (2010) (111)
- Quantification of CBFβ/MYH11 fusion transcript by Real Time RT-PCR in patients with INV(16) acute myeloid leukemia (2001) (110)
- Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia (2013) (109)
- R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis. (2021) (108)
- Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review (2007) (108)
- Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. (2004) (108)
- Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. (2007) (107)
- A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. (2016) (107)
- Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia (2015) (107)
- Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403 (2014) (105)
- Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. (2013) (104)
- Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. (2011) (104)
- RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. (2012) (103)
- Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. (2013) (103)
- Epigenetics in acute myeloid leukemia. (2008) (100)
- Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial (2017) (100)
- Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. (2013) (98)
- Bone Marrow Niche Trafficking of miR-126 Controls Self-Renewal of Leukemia Stem Cells in Chronic Myelogenous Leukemia (2018) (96)
- A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. (2014) (95)
- Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. (2006) (95)
- Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2. (2009) (94)
- Targeting Leukemia Stem Cells in vivo with AntagomiR-126 Nanoparticles in Acute Myeloid Leukemia (2015) (93)
- Core binding factor acute myeloid leukemia. (2006) (93)
- Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia (2008) (91)
- Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance) (2014) (90)
- Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia (2009) (89)
- Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. (2010) (88)
- Acute myeloid leukemia, version 2.2013. (2013) (86)
- Dose escalation of lenalidomide in relapsed or refractory acute leukemias. (2010) (86)
- Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. (2012) (85)
- DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. (2008) (84)
- Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia. (2019) (84)
- Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. (2014) (84)
- Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. (2012) (80)
- Potential of microRNAs for cancer diagnostics, prognostication and therapy (2012) (80)
- Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. (2016) (78)
- Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia. (2015) (77)
- Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia. (2017) (76)
- Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. (2009) (76)
- Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing. (2010) (76)
- Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instability. (2012) (76)
- Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. (2006) (75)
- Efflux of Depsipeptide FK228 (FR901228, NSC-630176) Is Mediated by P-Glycoprotein and Multidrug Resistance-Associated Protein 1 (2005) (74)
- Targeting AML1/ETO-Histone Deacetylase Repressor Complex: A Novel Mechanism for Valproic Acid-Mediated Gene Expression and Cellular Differentiation in AML1/ETO-Positive Acute Myeloid Leukemia Cells (2007) (73)
- A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia (2008) (72)
- Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. (2009) (72)
- NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. (2011) (72)
- HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation. (2015) (72)
- Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method (2007) (70)
- Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia (2014) (69)
- Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts. (2016) (69)
- Chemoresistance to Depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-Ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] Is Mediated by Reversible MDR1 Induction in Human Cancer Cell Lines (2005) (68)
- Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling (2011) (68)
- Characterization and quantification of Bcl-2 antisense G3139 and metabolites in plasma and urine by ion-pair reversed phase HPLC coupled with electrospray ion-trap mass spectrometry. (2005) (66)
- A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. (2006) (65)
- miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. (2012) (65)
- Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. (2016) (65)
- Differential expression of histone post-translational modifications in acute myeloid and chronic lymphocytic leukemia determined by high-pressure liquid chromatography and mass spectrometry (2003) (64)
- Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene (1999) (63)
- Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. (2001) (63)
- Detection of unique ALL1 (MLL) fusion transcripts in normal human bone marrow and blood: distinct origin of normal versus leukemic ALL1 fusion transcripts. (1998) (63)
- NCCN Clinical Practice Guidelines Acute myeloid leukemia. (2012) (63)
- Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications (1999) (62)
- Myeloid Cell-Targeted miR-146a Mimic Inhibits NF-kB-Driven Inflammation and Leukemia Progression in Vivo. (2019) (62)
- Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality (2007) (61)
- SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function. (2018) (61)
- Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: dose‐limiting myelosuppression without evidence of DNA hypomethylation (2010) (61)
- Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. (2014) (61)
- Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. (2013) (60)
- A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old (2007) (60)
- A LC-MS/MS Method for the Analysis of Intracellular Nucleoside Triphosphate Levels (2007) (59)
- Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results. (2020) (59)
- Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines. (2003) (58)
- Molecular and Clinical Advances in Core Binding Factor Primary Acute Myeloid Leukemia: A Paradigm for Translational Research in Malignant Hematology (2000) (58)
- Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. (2013) (57)
- A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia (2013) (57)
- Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. (2008) (57)
- Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503) (2016) (56)
- Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. (2008) (56)
- Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study (2019) (56)
- SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. (2014) (55)
- Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis (2015) (54)
- A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. (2017) (53)
- Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia (2015) (53)
- Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias (2010) (53)
- Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia (2016) (52)
- CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma (2016) (52)
- Acute Myeloid Leukemia (2017) (52)
- Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia (2013) (50)
- Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia (2014) (50)
- Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. (2011) (50)
- FTY 720 , a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome – positive acute lymphocytic leukemia (2007) (49)
- The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results. (2019) (49)
- Molecular signatures in acute myeloid leukemia (2009) (49)
- MicroRNA expression in acute myeloid leukemia (2009) (49)
- A Specific Picomolar Hybridization-Based ELISA Assay for the Determination of Phosphorothioate Oligonucleotides in Plasma and Cellular Matrices (2006) (49)
- Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. (2018) (48)
- A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia. (2007) (48)
- Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults (2013) (48)
- Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells. (2007) (48)
- GAS6 expression identifies high-risk adult AML patients: potential implications for therapy (2013) (48)
- SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML) (2016) (48)
- Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia. (2013) (48)
- Detection of extracellular RNAs in cancer and viral infection via tethered cationic lipoplex nanoparticles containing molecular beacons. (2013) (47)
- Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl 1 stability and drug resistance by modulation of protein phosphatase 2 A * (2011) (47)
- C/EBPα and DEK coordinately regulate myeloid differentiation. (2012) (47)
- The thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO. (2012) (46)
- PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD+ Acute Myeloid Leukemia. (2019) (46)
- Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia (2019) (46)
- Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells. (2014) (46)
- Characterization of Silvestrol Pharmacokinetics in Mice Using Liquid Chromatography–Tandem Mass Spectrometry (2011) (45)
- Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia. (2010) (45)
- Purification, Identification, and Cloning of Lysoplasmalogenase, the Enzyme That Catalyzes Hydrolysis of the Vinyl Ether Bond of Lysoplasmalogen* (2011) (45)
- TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia. (2009) (44)
- Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS. (2007) (44)
- Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. (2014) (44)
- A novel liposomal formulation of flavopiridol. (2009) (44)
- An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations (2017) (44)
- Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. (2009) (43)
- The Mll partial tandem duplication: differential, tissue-specific activity in the presence or absence of the wild-type allele. (2008) (43)
- Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. (2015) (42)
- Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665 (2016) (42)
- The Combination of the Proteasome Inhibitor Bortezomib and the Bcl-2 Antisense Molecule Oblimersen Sensitizes Human B-Cell Lymphomas to Cyclophosphamide (2006) (42)
- Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia (2008) (42)
- Cellular Uptake and Intracellular Levels of the Bcl-2 Antisense G3139 in Cultured Cells and Treated Patients with Acute Myeloid Leukemia (2005) (42)
- Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting (2019) (42)
- Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells. (2016) (41)
- Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use (2018) (41)
- Venetoclax and hypomethylating agents in TP53‐mutated acute myeloid leukaemia (2019) (41)
- inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. (2013) (41)
- Tumor intrinsic and extrinsic determinants of response to blinatumomab in adults with B-ALL. (2020) (41)
- Sp1/NF κ B/HDAC/ miR-29b Regulatory Network in KIT-driven Myeloid Leukemia (2010) (40)
- Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients (2021) (40)
- Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance) (2014) (40)
- Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. (2006) (39)
- MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen. (2019) (39)
- High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia. (2011) (39)
- Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients (2018) (38)
- Transferrin Receptor Targeted Lipopolyplexes for Delivery of Antisense Oligonucleotide G3139 in a Murine K562 Xenograft Model (2009) (38)
- Liquid chromatography mass spectrometry profiling of histones. (2007) (37)
- Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. (2019) (37)
- Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia (2017) (37)
- Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia (2016) (37)
- Transcriptional control of human T‐BET expression: The role of Sp1 (2007) (36)
- HDAC8 regulates long-term hematopoietic stem-cell maintenance under stress by modulating p53 activity. (2017) (35)
- Methods for high-throughput MethylCap-Seq data analysis (2012) (35)
- The Bcl‐2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML (2019) (35)
- Molecular prognostic factors in cytogenetically normal acute myeloid leukemia (2012) (34)
- Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). (2020) (34)
- Depsipeptide inhibits migration of primary and metastatic uveal melanoma cell lines in vitro: a potential strategy for uveal melanoma (2005) (34)
- Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells. (2012) (34)
- Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial (2021) (34)
- Acute Myeloid Leukemia: Biologic, Prognostic, and Therapeutic Insights. (2016) (34)
- Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes. (2006) (34)
- Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification (2014) (34)
- Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies (2012) (33)
- Targeting epigenetic changes in acute myeloid leukemia. (2005) (33)
- Understanding the Molecular Basis of Imatinib Mesylate Therapy in Chronic Myelogenous Leukemia and the Related Mechanisms of Resistance (2003) (33)
- Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia (2016) (33)
- CD94 Defines Phenotypically and Functionally Distinct Mouse NK Cell Subsets1 (2009) (33)
- A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804 (2009) (32)
- Daratumumab induces CD38 internalization and impairs myeloma cell adhesion (2018) (32)
- Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. (2020) (32)
- Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia (2015) (32)
- The emerging story of acute lymphoblastic leukemia among the Latin American population - biological and clinical implications. (2019) (30)
- Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3, GATA6, and TWIST1 in the Sezary Syndrome. (2015) (30)
- MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias. (2009) (30)
- High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. (2011) (30)
- The partial nontandem duplication of the MLL (ALL1) gene is a novel rearrangement that generates three distinct fusion transcripts in B-cell acute lymphoblastic leukemia. (2001) (29)
- Synthetic microRNA cassette dosing: pharmacokinetics, tissue distribution and bioactivity. (2012) (29)
- Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood. (2003) (29)
- Defining the "absence" of the CBFbeta/MYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: a call for definitions. (1997) (28)
- Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myeloid leukemia. (2020) (28)
- Metabolism of GTI-2040, a phosphorothioate oligonucleotide antisense, using ion-pair reversed phase high performance liquid chromatography (HPLC) coupled with electrospray ion-trap mass spectrometry (2008) (28)
- Prognostic Importance of MN 1 Transcript Levels , and Biologic Insights From MN 1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia : A Cancer and Leukemia Group B Study (2009) (28)
- Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia (2017) (28)
- A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents (2008) (28)
- Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). (2018) (28)
- Fever and neutropenia clinical practice guidelines. (2004) (27)
- Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. (2020) (27)
- Quantification of regional DNA methylation by liquid chromatography/tandem mass spectrometry. (2009) (27)
- Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia (2013) (27)
- Validation of an LC‐MS based approach for profiling histones in chronic lymphocytic leukemia (2009) (26)
- Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (≥60 years[y]) and Younger (<60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study. (2009) (26)
- Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease. (2013) (26)
- Recombinant interleukin‐2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808 (2013) (26)
- Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT–PCR useful clinically? (2003) (26)
- MiR-16 regulates crosstalk in NF-kB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages. (2019) (26)
- Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia. (2017) (25)
- A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808. (2005) (25)
- Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia (2014) (25)
- Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia (2012) (25)
- Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study (2011) (24)
- CBFβ-SMMHC creates aberrant megakaryocyte-erythroid progenitors prone to leukemia initiation in mice. (2016) (24)
- NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation (2014) (24)
- Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status (2017) (24)
- Nanochannel Electroporation as a Platform for Living Cell Interrogation in Acute Myeloid Leukemia (2015) (23)
- Efficient delivery of antisense oligodeoxyribonucleotide g3139 by human serum albumin-coated liposomes. (2009) (23)
- Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumab. (2020) (22)
- The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia (2012) (22)
- CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia. (2015) (22)
- Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing. (2019) (22)
- Targeting human clonogenic acute myelogenous leukemia cells via folate conjugated liposomes combined with receptor modulation by all-trans retinoic acid. (2010) (22)
- Venetoclax and hypomethylating agents in FLT3‐mutated acute myeloid leukemia (2020) (22)
- Intronic miR-3151 Within BAALC Drives Leukemogenesis by Deregulating the TP53 Pathway (2014) (21)
- Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL (2019) (21)
- Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions. (2020) (21)
- Hyperglycemia in Patients with Acute Myeloid Leukemia Is Associated with Increased Hospital Mortality. (2006) (21)
- Treatment of Acute Lymphoblastic Leukemia in Adults: Applying Lessons Learned in Children. (2016) (21)
- Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model (2017) (21)
- The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations (2017) (21)
- Histone H4 N-terminal acetylation in Kasumi-1 cells treated with depsipeptide determined by acetic acid-urea polyacrylamide gel electrophoresis, amino acid coded mass tagging, and mass spectrometry. (2007) (21)
- The role of ErbB3 binding protein 1 in cancer: Friend or foe? (2018) (20)
- Histone H4 acetylation dynamics determined by stable isotope labeling with amino acids in cell culture and mass spectrometry. (2007) (20)
- Second autologous stem cell transplant for multiply relapsed Hodgkin's disease (2002) (19)
- New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: Cancer and leukemia group B 8461 (2013) (19)
- Characterization of leukemia-associated Rho guanine nucleotide exchange factor (LARG) expression during murine development (2003) (19)
- Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target (2013) (19)
- AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results (2021) (19)
- Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine (2021) (19)
- High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia (2005) (19)
- CAR22/19 Cocktail Therapy for Patients with Refractory/Relapsed B-Cell Malignancies (2018) (18)
- A Novel Ultrasensitive Hybridization-Based ELISA Method for 2-Methoxyphosphorothiolate MicroRNAs and Its In vitro and In vivo Application (2010) (18)
- High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation. (2006) (18)
- ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in CLL mouse model. (2019) (18)
- Loss of C/EBPα and Favorable Prognosis of Acute Myeloid Leukemias: A Biological Paradox (2004) (18)
- Targeting PRMT1-Mediated FLT3 Methylation Disrupts Maintenance of MLL- rearranged Acute Lymphoblastic Leukemia. (2019) (17)
- Impact of molecular prognostic factors in cytogenetically normal acute myeloid leukemia at diagnosis and relapse (2011) (17)
- Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461. (2004) (17)
- Correction: Estrogen Mediated-Activation of miR-191/425 Cluster Modulates Tumorigenicity of Breast Cancer Cells Depending on Estrogen Receptor Status (2013) (16)
- In Vivo Quantification of Active Decitabine-Triphosphate Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (2012) (16)
- State-Transition Analysis of Time-Sequential Gene Expression Identifies Critical Points That Predict Development of Acute Myeloid Leukemia (2020) (16)
- Interplay of RUNX 1 / MTG 8 and DNA Methyltransferase 1 in Acute Myeloid Leukemia (2005) (16)
- Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant. (2021) (16)
- Mutations of KIT tyrosine kinase (TK) gene predict relapse in adult patients (pts) with core binding factor acute myeloid leukemia (CBF AML): A Cancer and Leukemia Group B (CALGB) study. (2006) (16)
- Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia (2021) (16)
- miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib. (2014) (15)
- Targeting AML 1 / ETO-Histone Deacetylase Repressor Complex : A Novel Mechanism for Valproic Acid-Mediated Gene Expression and Cellular Differentiation in AML 1 / ETO-Positive Acute Myeloid Leukemia Cells (2007) (15)
- Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia (2019) (15)
- BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment (2010) (15)
- Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study (2012) (15)
- Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit) (2018) (15)
- Assaying pharmacodynamic endpoints with targeted therapy: Flavopiridol and 17AAG induced dephosphorylation of histone H1.5 in acute myeloid leukemia (2010) (15)
- Radiation-free regimens result in similar outcomes of allogeneic hematopoietic progenitor cell transplantation in patients aged ≥50 years compared to younger adults with low-risk disease (2003) (14)
- Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents (2016) (14)
- ILC1s Control Leukemia Stem Cell Fate and Limit Development of AML (2022) (14)
- 8‐chloro‐adenosine activity in FLT3‐ITD acute myeloid leukemia (2019) (13)
- The Large Zinc Finger Protein ZAS3 Is a Critical Modulator of Osteoclastogenesis (2011) (13)
- Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study (2017) (13)
- Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage-Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. (2020) (13)
- Statistical methods for detecting differentially methylated regions based on MethylCap-seq data (2016) (13)
- 5-Aza-2'-deoxycytidine and depsipeptide synergistically induce expression of BIK (BCL2-interacting killer). (2006) (13)
- A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485 (2017) (13)
- Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). (2021) (13)
- Introduction: Acute Myeloid Leukemia (2008) (12)
- The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement (2020) (12)
- Low Meningioma 1 (MN1) gene expression to predict outcome in cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) study (2008) (12)
- Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting. (2019) (12)
- New approaches in acute myeloid leukemia. (2008) (12)
- PrEMeR-CG: inferring nucleotide level DNA methylation values from MethylCap-seq data (2014) (11)
- Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. (2021) (11)
- Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome (2013) (11)
- Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance) (2012) (11)
- Efficacy and safety of an anti-FLT3 antibody (LY3012218) in patients with relapsed acute myeloid leukemia. (2015) (11)
- Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. (2016) (11)
- Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. (2018) (11)
- Immune Mediated Mechanisms of Resistance to Daratumumab (2018) (11)
- Enrichment-based DNA methylation analysis using next-generation sequencing: sample exclusion, estimating changes in global methylation, and the contribution of replicate lanes (2012) (11)
- Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34 + /CD38 − Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABL– independent Signals (2008) (11)
- Independent Validation of Prognostic Relevance of a Previously Reported Gene-Expression Signature in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Cancer and Leukemia Group B (CALGB) Study. (2005) (11)
- Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance (2021) (10)
- Philadelphia chromosome as a recurrent event among therapy‐related acute leukemia (2017) (10)
- NKp 46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human (2011) (10)
- Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia (2019) (10)
- Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML) receiving intensive chemotherapy on a cooperative group trial: CALGB 361006 (Alliance). (2014) (10)
- Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia (2021) (10)
- Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). (2021) (9)
- Enzyme Kinetics of GTI-2040, a Phosphorothioate Oligonucleotide Targeting Ribonucleotide Reductase (2008) (9)
- New targets of therapy in T-cell lymphomas. (2010) (9)
- Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). (2019) (9)
- Induced Apoptosis Investigation in Wild-type and FLT3-ITD Acute Myeloid Leukemia Cells by Nanochannel Electroporation and Single-cell qRT-PCR. (2016) (9)
- Acute myeloid leukemia. (2008) (9)
- High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults (2015) (9)
- Phase I study of AR-42 and decitabine in acute myeloid leukemia (2020) (9)
- Therapy-related myelodysplasia and leukemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation (2004) (9)
- Ebp1 p48 promotes oncogenic activities in human colon cancer cells through regulation of TIF‐90‐mediated ribosomal RNA synthesis (2019) (9)
- In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline (2013) (9)
- Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis (2019) (9)
- Long term outcomes of patients with Acute Myeloid Leukemia treated with myeloablative FTBI based conditioning with Tacrolimus and sirolimus based GVHD prophylaxis regimen: 6 year follow up from Single Center. (2020) (9)
- Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia (2019) (9)
- Association of abnormal cytogenetics at date of morphologic complete remission (CR) with overall (OS), disease-free survival (DFS) and higher relapse rate in acute myeloid leukemia (AML): Results from Cancer and Leukemia Group B (CALGB) 8461 (2004) (8)
- Discovery of proangiogenic CD44+mesenchymal cancer stem cells in an acute myeloid leukemia patient’s bone marrow (2020) (8)
- Genomic Characterization and Experimental Modeling Of BCR-ABL1 -Like Acute Lymphoblastic Leukemia (2013) (8)
- A novel vitamin D gene therapy for acute myeloid leukemia (2020) (8)
- Simultaneous metabolic labeling of cells with multiple amino acids: Localization and dynamics of histone acetylation and methylation (2007) (8)
- Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001) (2015) (8)
- Biochemical Modulation of Aracytidine (Ara-C) Effects by GTI-2040, a Ribonucleotide Reductase Inhibitor, in K562 Human Leukemia Cells (2011) (8)
- Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age≥60) with Previously Untreated Acute Myeloid Leukemia (AML) (2008) (8)
- Liposomal Targeted Delivery Overcomes Immunostimulatory Effects of Oligonucleotide Based Therapy In Chronic Lymphocytic Leukemia. (2010) (8)
- Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study (2010) (8)
- Loss of C/EBP alpha and favorable prognosis of acute myeloid leukemias: a biological paradox. (2004) (8)
- Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia. (2020) (8)
- Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Compared to Chemotherapy Only in Acute Myeloid Leukemia (AML) Patients 60 Years and Older: A Center for International Blood and Marrow Transplantation Research (CIBMTR)/ Cancer and Leukemia Group B (CALGB) Study. (2009) (8)
- Acute myeloid leukemia. Introduction. (2008) (7)
- Phase I Study of Low Dose Decitabine in Patients with Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity. (2005) (7)
- Iron Overload is Associated with Delayed Engraftment and Increased Non-Relapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation. (2020) (7)
- A scalable, flexible workflow for MethylCap-seq data analysis (2011) (7)
- Cytoplasmic DROSHA and Non-canonical Mechanisms of MiR-155 Biogenesis in FLT3-ITD Acute Myeloid Leukemia (2021) (7)
- Preclinical Development of LNA Antimir-155 (MRG-106) in Acute Myeloid Leukemia (2015) (7)
- Determination of cellular uptake and intracellular levels of Cenersen (Aezea(®), EL625), a p53 antisense oligonucleotide in acute myeloid leukemia cells. (2012) (7)
- Acute Myeloid Leukemia , Version 3 . 2019 (2019) (7)
- Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101 (2013) (7)
- Acute Myeloid Leukemia : Biologic , Prognostic , and Therapeutic Insights Review (2017) (7)
- More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine. (2019) (7)
- Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide (2022) (7)
- The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. (2022) (7)
- PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives (2010) (7)
- Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations. (2019) (7)
- Response to Venetoclax and Hypomethylating Agents Among Prognostic Risk Groups and Genetic Subtypes of Acute Myeloid Leukemia (2018) (7)
- Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts) (2011) (6)
- Disulfide-linked liposomes: effective delivery vehicle for Bcl-2 antisense oligodeoxyribonucleotide G3139. (2010) (6)
- Abstract PR14: CD123CAR displays clinical activity in relapsed/refractory (r/r) acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN): Safety and efficacy results from a phase 1 study (2020) (6)
- HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML (2020) (6)
- MicroRNA 181a (miR-181a) expression as a prognosticator in cytogenetically normal acute myeloid leukemia (CN AML). (2009) (6)
- Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. (2021) (6)
- Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation (2021) (6)
- FTY720 Restores PP2A Tumor Suppressor Activity in Polycythemia Vera CD34+ Progenitors Through Inhibition of Jak2 V617F- and PI-3Kγ-Dependent SET Serine Phosphorylation and Enhancement of NOS-Dependent PP2A Tyrosine Nitration (2011) (6)
- The Biology Behind Understanding the Molecular Basis of Imatinib Mesylate Therapy in Chronic Myelogenous Leukemia and the Related Mechanisms of Resistance 1 (2003) (6)
- Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation. (2019) (5)
- Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia (2014) (5)
- Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance) (2012) (5)
- Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation (2017) (5)
- Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML (2021) (5)
- MicroRNA-181a Targets TEL/AML1 Expression and Impairs Cell Proliferation in t(12;21) Acute Lymphocytic Leukemia (ALL) Cells. (2009) (5)
- Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA‐Ven) or liposomal daunorubicin‐cytarabine (CPX‐351) (2021) (5)
- The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies. (2019) (5)
- A 75-year-old woman with thoracic spinal cord compression and chloroma (granulocytic sarcoma). (2012) (5)
- Outcome prediction in adult core binding factor (CBF) acute myeloid leukemia (AML) with gene expression profiling: A Cancer and Leukemia Group B (CALGB) study (2007) (5)
- Population pharmacokinetics of lenalidomide in patients with B‐cell malignancies (2019) (5)
- Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia (2021) (5)
- FTY720 but Not Its Immunosuppressive Phosphorylated Form FTY720-P Exerts Anti-Leukemic Activity towards Ph(+) and Ph(−) Myeloproliferative Disorders through Reactivation of the PP2A Tumor Suppressor. (2009) (5)
- Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study. (2009) (5)
- Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001) (2013) (5)
- Effective Novel Fto Inhibitors Show Potent Anti-Cancer Efficacy and Suppress Drug Resistance (2019) (5)
- implications for Axl as a potential therapeutic target FLT3 internal tandem duplication in human acute myeloid leukemia: Inhibition of the receptor tyrosine kinase Axl impedes activation of the (2013) (4)
- NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML). (2016) (4)
- Abstract LB-109: BCR-ABL1 kinase activity but not its expression is dispensable for Ph+ quiescent stem cell survival which depends on the PP2A-controlled Jak2 activation and is sensitive to FTY720 treatment (2011) (4)
- miR-3151 Interplays With its Host Gene BAALC and Independently Impacts on Outcome of Older Patients With Cytogenetically Normal Acute Myeloid Leukemia by Direct Deregulation of TP53 (2014) (4)
- METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism. (2023) (4)
- Final Results of a Dose Escalation Study of Flavopiridol in Acute Leukemias Using a Novel Treatment Schedule. (2007) (4)
- A Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase (RNR) in Combination with High-Dose Cytarabine (HiDAC) in Relapsed or Refractory Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamic (PD) and Clinical Results. (2005) (4)
- Corrigendum to "Efficient delivery of a Bcl2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor targeted liposomes" [Journal of Controlled Release 112 (2006) 199-207] (DOI: 10.1016/j.jconrel.2006.02.011) (2006) (4)
- Cancer Therapy : Preclinical Targeted Delivery of microRNA-29 b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles : A Novel Therapeutic Strategy in Acute Myeloid Leukemia (2013) (4)
- Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [≥60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study. (2009) (4)
- Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical HCT with Post-Transplant Cyclophosphamide (2021) (4)
- Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) (2022) (4)
- Wilms Tumor 1 (WT1) Gene Mutations Predict Poor Outcome in Adults with Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): A Cancer and Leukemia Group B (CALGB) Study. (2007) (4)
- High BAALC expression associates with other molecular prognostic markers, poor outcome and a distinct gene expression signature in cytogenetically normal acute myeloid leukemia (CN AML): A Cancer and Leukemia Group B (CALGB) study (2007) (4)
- Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies. (2021) (4)
- Genomic Determinants of Response to Blinatumomab in Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia in Adults (2018) (4)
- Molecular markers in acute myeloid leukemia. (2009) (4)
- Abstract 3839: Nuclear export (karyopherin) inhibitors: A novel therapeutic strategy for treating Philadelphia-positive (Ph+) acute leukemias (2012) (4)
- Management of patients with cytogenetically normal acute myeloid leukemia who have neither favorable nor unfavorable markers. (2014) (4)
- Disruption of dNTPs Homeostasis by Ribonucleotide Reductase Hyperactivation Overcomes AML Differentiation Blockade. (2022) (4)
- Depsipeptide ( FR 901228 ) Inhibits Proliferation and Induces Apoptosis in Primary and Metastatic Human Uveal Melanoma Cell Lines (2003) (4)
- Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more postremission chemotherapy courses: Analysis of four CALGB studies. (2010) (4)
- Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable‐risk acute myeloid leukemia (2020) (4)
- Total Marrow and Lymphoid Irradiation with Post-Transplant Cyclophosphamide for Patients with AML in Remission. (2022) (4)
- Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T Cell Therapy in Adults with high-risk Relapsed/Refractory ALL. (2022) (4)
- Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study (2021) (4)
- Core‐binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure (2020) (4)
- A Novel Regimen for Acute Myeloid Leukemia with MLL Partial Tandem Duplication: Results of a Phase 1 Study NCI 8485 (2016) (3)
- Roadmap on plasticity and epigenetics in cancer (2022) (3)
- Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614) (2018) (3)
- The Mll PTD and Flt3 ITD Double Knock-In Mouse Develops Acute Leukemia and Recapitulates Phenotypic, Molecular and Epigenetic Characteristics of the Counterpart Human Acute Myeloid Leukemia (2010) (3)
- Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy (2020) (3)
- Anti-IL1RAP/CD3 Bispecific Antibody (BsAb) Is a Promising Novel and Effective Therapy for Acute Myeloid Leukemia (AML) (2017) (3)
- Targeting BRD4 in acute myeloid leukemia with partial tandem duplication of the MLL gene (2021) (3)
- Proteomic, Gene Expression, and Micro-RNA Analysis Of Bone Marrow Mesenchymal Stromal Cells In Acute Myeloid Leukemia Identifies Pro-Inflammatory, Pro-Survival Signatures In Vitro and In Vivo (2013) (3)
- BH3 Profiling Predicts On-Target Cell Death Due To Selective Inhibition Of BCL-2 By ABT-199 In Acute Myelogenous Leukemia (2013) (3)
- Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy (2018) (3)
- Evidence of MicroRNA-29b and Sp1/NFκB-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications. (2009) (3)
- MiR-126 Promotes Leukemogenesis in Inv(16) Acute Myeloid Leukemia (2017) (3)
- Identification of a CD133−CD55− population functions as a fetal common skeletal progenitor (2016) (3)
- MiRNA-29b Targets MCL-1 and Is Down-Regulated in Chemotherapy-Resistant Acute Myeloid Leukemia (AML). (2007) (3)
- Phase I study of a novel, pharmacokinetically derived schedule of flavopiridol in acute leukemias: Clinical efficacy including hyperacute tumor lysis, pharmacokinetics, and pharmacodynamics. (2006) (3)
- Panobinostat, An Oral Pan-Histone Deacetylase (HDAC) Inhibitor Activates a Microrna Signature That Targets Rad51 To Attenuate Homologous DNA Repair and Sensitize AML Cells To Sapacitabine (2013) (3)
- Strategies to Inhibit Alloantibody Production in Alloprimed Murine Recipients of Hematopoietic Stem Cell Grafts (2015) (3)
- Exosome-driven lipolysis and bone marrow niche remodeling support leukemia expansion (2020) (3)
- Acute Myeloid Leukemia (AML) with 9q Aberrations Occuring within a Non-Complex Karyotype Is Highly Associated with CEBPA and NPM1 Mutations - A Joint Analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB). (2007) (3)
- Targeted Delivery of miRNA Antagonists to Myeloid Cells In Vitro and In Vivo. (2019) (3)
- Response: Conflicting data on the prognostic significance of FLT3-TKD mutations in cytogenetically normal acute myeloid leukemia (CN-AML) might be related to many factors, including techniques used to detect FLT3-TKD, differences in patient populations studied, and treatment regimens (2008) (3)
- Refractory primary autoimmune myelofibrosis treated with ruxolitinib (2021) (3)
- Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes (2021) (3)
- Pharmacologic Restoration of PP2A Activity and Interference with the SET-PP2A Interplay by FTY720 and Its Non-Immunosuppressive Derivative as a Novel and Efficient Therapy for Ph-Negative Myeloproliferative Disorders (2010) (3)
- Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL (2022) (3)
- Proteomics Profiling of Leukemia Derived Exosomes: A Potential Role in Leukemic Transformation (2015) (3)
- Arginase-mediated "field" defects in AML. (2013) (3)
- ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet ‘Favorable9 Genetic Category (2011) (3)
- A Retrospective Study of Venetoclax-Based Salvage Regimen As a Bridge to Allogeneic Hematopoietic Cell Transplantation (HCT) in High-Risk Acute Myeloid Leukemia (AML) Patients (2019) (3)
- Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute Myeloid Leukemia (AML) (2011) (3)
- Patients (pts) with acute myeloid leukemia (AML) and mutant RAS benefit from high-dose cytarabine (HDAC) intensification: A Cancer and Leukemia Group B (CALGB) study (2005) (3)
- Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT. (2021) (3)
- Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma (2013) (3)
- Challenges for Conducting Clinical Trials Evaluating Maintenance Chemotherapy In Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study (2010) (3)
- Prognostic Significance of Unbalanced Chromosome Abnormalities Used by 2008 World Health Organization (WHO) Classification to Define “Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes” in Adults: a Cancer and Leukemia Group B (CALGB) Study. (2009) (2)
- Targeting miR‐126 disrupts maintenance of myelodysplastic syndrome stem and progenitor cells (2021) (2)
- Ex vivo isolation, expansion and bioengineering of CCR7+CD95-/or CD62L+CD45RA+ tumor infiltrating lymphocytes from acute myeloid leukemia patients’ bone marrow (2021) (2)
- Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML) (2020) (2)
- Combined Pharmacologic Inhibition of Bcl-Xl/Bcl-2 and mTORC1/2 Survival Signals Trigger Apoptosis in BCR-ABL1 + in Vitro Models of Blast Crisis Chronic Myelogenous Leukemia (CML-BC), and Primary CD34 + /CD38 − Stem and CD34 + progenitor Cells From CML-BC Patients (2011) (2)
- Efficacy of a novel schedule of decitabine in previously untreated AML, age 60 or older. (2009) (2)
- Expression in Acute Myeloid Leukemia α Epigenetic Modification of CCAAT / Enhancer Binding Protein (2008) (2)
- Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and Microrna (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study (2010) (2)
- Co-Expression of BAALC with ERG, TCF4, and CD133 Indicates a Shared Pathway in Acute Myeloid and Lymphoblastic Leukemia. (2005) (2)
- Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis (2019) (2)
- ALL-440: Promising Safety and Efficacy Results from an Ongoing Phase 1/2 Study of Pembrolizumab in Combination with Blinatumomab in Patients (pts) with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) (2021) (2)
- Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia (2005) (2)
- A Phase II Trial of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation (2020) (2)
- Incidence of Extramedullary Relapse of Acute Myeloid Leukemia Following Transplantation with Busulfan-Based Conditioning Regimens. (2004) (2)
- Synergy of Venetoclax and 8-Chloro-Adenosine in AML: The Interplay of rRNA Inhibition and Fatty Acid Metabolism (2022) (2)
- Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors (2022) (2)
- Abstract 5540: Preclinical investigation of the novel histone deacetylase (HDAC) inhibitor AR-42 in the treatment of cancer-induced cachexia (2014) (2)
- Mir-155 Expression Is Associated with Chemoimmunotherapy Outcome and Is Modulated By Bruton’s Tyrosine Kinase Inhibition with Ibrutinib (2014) (2)
- Immunophenotype of acute lymphoblastic leukemia in minorities‐ analysis from the SEER database (2021) (2)
- 8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth Via Novel RNA- and ATP-Directed Mechanisms: A Novel Therapeutic Approach for AML (2015) (2)
- Dynamic patterns of microRNA expression during acute myeloid leukemia state-transition (2022) (2)
- Tumor Antigen ROR1 Targeted Delivery of MiR-29b in Chronic Lymphocytic Leukemia Induces Epigenetic Reprograming Resulting in Cell Cycle Arrest (2017) (2)
- The Receptor Tyrosine Kinase Axl Is Required for Resistance to FLT3-Targeted Therapy in Acute Myeloid Leukemia (2014) (2)
- Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML (2015) (2)
- Programmable siRNA pro-drugs that activate RNAi activity in response to specific cellular RNA biomarkers (2022) (2)
- Spred1 deficit promotes treatment resistance and transformation of chronic phase CML (2021) (2)
- Decitabine Priming Enhances The Antileukemic Effects Of The Selective Inhibitor Of Nuclear Export (SINE) CRM1/XPO1 Antagonist (Selinexor) In Acute Myeloid Leukemia (AML) (2013) (2)
- Abstract 1584: Targeting protein arginine methyltransferase 5 (PRMT5) enzyme over expression in high grade astrocytomas (2010) (2)
- prognostically prioritized molecular classification ? acute myeloid leukemia with normal cytogenetics : are we ready for a Clinical relevance of mutations and gene-expression changes in adult (2006) (2)
- Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia. (2009) (2)
- A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation (2008) (2)
- SPARC contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML) (2012) (2)
- Overexpression of the ERG Gene Is an Adverse Prognostic Factor in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Cancer and Leukemia Group B Study (CALGB). (2005) (2)
- Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML) (2010) (2)
- Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax. (2022) (2)
- A Phase I Dose Escalation Study of Lenalidomide Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation (2014) (2)
- An 86-Probe Gene Expression Signature Can Predict Survival in AML with Normal Karyotype Independently of FLT3 ITD and NPM1 Mutation Status - A Collaborative Study from the AMLCG and CALGB Study Groups. (2007) (2)
- Donor derived leukemia in allogeneic transplantation (2021) (2)
- Requirement of GTP binding for TIF‐90‐regulated ribosomal RNA synthesis and oncogenic activities in human colon cancer cells (2020) (2)
- Epigenetic Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a Phase I Study of Bortezomib in Combination with 5-Azacytidine in Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML). (2009) (2)
- Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial (2020) (2)
- Superior therapy response predictions for patients with myelodysplastic syndrome (MDS) using Cellworks Singula: MyCare-009-02. (2020) (2)
- Increased Expression Of IL-15 Promotes Cutaneous T-Cell Lymphomagenesis Via The Upregulation Of Histone Deacetylases: Evidence For Successful Preclinical Targeting (2013) (2)
- Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma (2019) (2)
- Elucidation of the Molecular Mechanisms by Which Inflammatory and Anti-Inflammatory Monokines Regulate Interferon (IFN)- γ Production. (2004) (2)
- State-Transition Analysis of Time-Sequential microRNA Expression Predicts Development of Acute Myeloid Leukemia (2021) (2)
- Combination of Dasatinib with Conventional Chemotherapy Is Associated with a High Response Rate in High Risk Acute Myeloid Leukemia (AML) (2015) (2)
- Knockdown (KD) of Mir-126 Expression Enhances Tyrosine Kinase Inhibitor (TKI)-Mediated Targeting of Chronic Myelogenous Leukemia (CML) Stem Cells (2015) (2)
- FLT3 D835/I836 mutations predict worse disease-free survival (DFS) in younger adults with cytogenetically normal acute myeloid leukemia (CN AML) without FLT3 internal tandem duplications (ITD): A Cancer and Leukemia Group B (CALGB) study (2007) (2)
- MicroRNA networks in FLT3-ITD acute myeloid leukemia (2022) (2)
- BCR/ABL Dosage Hierarchically and Temporally Influences hnRNP A1, hnRNP K and hnRNP E2 Expression in Hematopoietic Stem and Progenitor Cells. (2009) (2)
- Tacrolimus initial steady state level in post-transplant cyclophosphamide based GvHD prophylaxis regimens (2021) (1)
- Prognostic Significance of IDH1 and IDH2 mutations in Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia (2016) (1)
- Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study (2018) (1)
- Not only TKI! Targeting FLT3-ITD by autophagy. (2016) (1)
- Genetics and Classification of Acute Myeloid Leukemia (2015) (1)
- High prevalence and inferior long‐term outcomes for TP53 mutations in therapy‐related acute lymphoblastic leukemia (2022) (1)
- Comparison Of Deep Sequencing and Allele-Specific Oligonucleotide PCR Methods For MRD Quantitation In Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma: CALGB 10403 and CALGB 59909 (Alliance) (2013) (1)
- Abstract 2717: Higher MN1 expression is an unfavorable prognosticator in older patients (Pts) with cytogenetically normal acute myeloid leukemia (CN-AML): A CALGB study (2010) (1)
- Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide - Possible Role of Donor KIR Genotypes (2018) (1)
- azacytidine activity in acute myeloid leukemia RNA-dependent inhibition of ribonucleotide reductase is a major (2012) (1)
- Human natural killer cell IFN-gamma production: Inhibition by TGF-beta involves SMAD-mediated downregulation of T-BET expression (2005) (1)
- Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents (2021) (1)
- Epigenetic priming: the target? (2011) (1)
- Biosimulation Using the Cellworks Computational Omics Biology Model (CBM) Identifies Novel Biomarkers to Inform Mitoxantrone, Etoposide, and Cytarabine (MEC)-Based Combination Therapy in Refractory & Relapsed Acute Myeloid Leukemia (AML) Patients (2021) (1)
- Methods for high-throughput MethylCap-Seq data analysis (2012) (1)
- 3.23 Targeted Nanoparticle Delivery Overcomes Off-Target Immunostimulatory Effects of Oligonucleotides and Improves Therapeutic Efficacy (2011) (1)
- The feasibility of additional CD19‐targeted cellular therapy in relapsed/refractory B‐ALL with re‐emergence of CD19 antigen after prior CD19‐negative relapse (2022) (1)
- Effect of germline ATM mutations on clonal hematopoiesis. (2019) (1)
- Supplementary Appendix for "Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia" (2014) (1)
- Identification of Medium-Sized Copy Number Alterations in Whole-Genome Sequencing (2014) (1)
- The Clinical Role of Micrornas (miRs) in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): miR-155 Upregulation Independently Identifies High-Risk Patients (Pts) (2012) (1)
- Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia (2015) (1)
- Dicer Ablations in Bone Marrow Niche Impair Hematopoietic Progenitor/Stem Cells and Induce Myelodysplasia in Young Mice but Are Dispensable for Adult Hematopoiesis (2015) (1)
- Decitabine-Induced Differentiation Syndrome in a Patient with Acute Myeloid Leukemia: A Case Report. (2004) (1)
- Cytokine gene polymorphisms are associated with response to blinatumomab in B‐cell acute lymphoblastic leukemia (2021) (1)
- Cytogenetic, Molecular and Clinical Features Associated with Rare CBFB-MYH11 Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16) (2011) (1)
- Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation (2022) (1)
- MicroRNA (miR) expression signatures in molecular subsets of cytogenetically normal (CN) acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study (2007) (1)
- Phase I Study Of The Combination Of Midostaurin, Bortezomib and Chemotherapy In Relapsed/Refractory Acute Myeloid Leukemia (AML): Targeting Aberrant Tyrosine Kinase Activity (2013) (1)
- Abstract 119: AR42, a histone deacetylase inhibitor (HDACI), increases microRNA (miR)-29b and sensitizes cells to decitabine (DAC) treatment: A novel epigenetic-targeting approach in acute myeloid leukemia (AML) (2012) (1)
- Somatic Mutational Landscape of AML with Inv(16) and t(8;21) Identifies Two Distinct Patterns in Relapse Tumors (2014) (1)
- High Response Rates and Transition to Transplant after Novel Targeted and Cellular Therapies in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia with Philadelphia-Like Fusions. (2023) (1)
- Publisher Correction: ILC1s control leukemia stem cell fate and limit development of AML (2022) (1)
- Homoharringtonine Synergizes Strongly with Venetoclax Against the Early T-Cell Progenitor Acute Lymphoblastic Leukemia：from Bench to Bed (2022) (1)
- Prognostic Significance of Karyotype in Octogenarian Patients (Pts) with Acute Myeloid Leukemia (AML)–An International Study (2011) (1)
- Acute Lymphocytic Leukemia in the Latin American Population (2018) (1)
- A Phase I Trial of Total Marrow and Lymphoid Irradiation (TMLI)-Based Transplant Conditioning in Patients (Pts) with Relapsed/Refractory Acute Leukemia (2015) (1)
- Abstract LB-225: Twisting stemness in AML using nanoparticle as a delivery system for siRNA targeting Twist (2020) (1)
- A 14q32.31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis By Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer Immunity (2019) (1)
- Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials. (2011) (1)
- phosphatase 2A Bcr-Abl1 stability and drug resistance by modulation of protein Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate (2011) (1)
- A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome (2020) (1)
- Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib (2022) (1)
- Post-transplant sinusoidal obstruction syndrome in adult patients with B-cell Acute Lymphoblastic Leukemia treated with pre-transplant Inotuzumab. (2023) (1)
- FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph 1 ALL Patients. (2006) (1)
- Serum Mir-29a Is Up-Regulated In Acute Graft Versus Host Disease (aGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) and Activates Dendritic Cells (DCs) (2013) (1)
- Transplant Outcomes in Patients with AML Carrying IDH 1 and 2 Mutations: Retrospective Study From a Single Center Experience (2018) (1)
- Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (2022) (1)
- Updated results of a phase I study of low dose decitabine and valproic acid (VA) in patients with acute myeloid leukemia (AML): Gene reexpression, demethylation, and clinical response. (2006) (1)
- HDAC8 Promotes MLL-Rearranged Acute Myeloid Leukemia By Inhibiting p53 Acetylation (2019) (1)
- Outcomes of Venetoclax and Hypomethylating Agents (HMA) in Adult Patients with KMT2A-Rearranged Leukemias (2021) (1)
- Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures, (2011) (1)
- myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study cytogenetically normal patients younger than 60 years with acute markers, poor outcome, and a distinct gene-expression signature in High BAALC expression associates with other molecular prognostic (2013) (1)
- Adverse Prognostic Impact of GAS6 Expression in De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance) (2012) (1)
- Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351) (2020) (1)
- Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine. (2012) (1)
- Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study (2023) (1)
- Inhibition of PRMT1 Mediated FLT3 Arginine Methylation As a Potent Therapeutic Strategy for MLL-r ALL (2018) (1)
- A Retrospective Study of Blinatumomab Based Salvage Regimen As a Bridge to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed and Refractory ALL (2019) (1)
- A Combined Molecular and Clinical Prognostic Index For Relapse and Survival In Cytogenetically Normal AML (PINA) (2013) (1)
- MiR- 16 Regulates Crosstalk in NF-κB Inflammatory Signaling between Myeloma Cells and Bone Marrow Macrophages (2017) (1)
- MicroRNA (miRNA)-29b Targets DNMT3A and B and Induces Re-Expression of the Hypermethylated ESR1 and p15 Genes in Acute Myeloid Leukemia (AML). (2007) (1)
- Abstract 2014: Modulation of DNA methyltransferases in leukemia cells by curcumin and its associated anti-leukemia activities (2011) (1)
- Long-term Outcomes of Allogeneic Hematopoietic Cell transplantation with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as GVHD prophylaxis in Patients with Acute Lymphoblastic Leukemia. (2020) (1)
- TET2 Activity Is Modulated By SIRT1-Mediated Protein Deacetylation: A Potential Therapeutic Target in Myelodysplastic Syndrome (2016) (1)
- Preliminary results of a phase I trial with dose escalated lenalidomide (L) in separate cohorts of relapsed acute leukemia (AL) or chronic lymphocytic leukemia (CLL): evidence of activity in acute myeloid leukemia (AML) and toxicity in CLL at starting dose (2008) (1)
- Identification of the Histone Deacetylase Inhibitor (HDACi), AR-42, as a Novel Anti-Leukemia Stem Cell Agent in Acute Myeloid Leukemia (AML). (2009) (1)
- Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML). (2012) (1)
- Abstract 5235: Identification of microRNA-3662as a novel tumor suppressor miR (2014) (1)
- Aberrant Gene Expression of BAALC and ERG in Older [≥60 Years (y)] De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study. (2009) (1)
- Abstract 1950: Suppression of RISC-independent decoy and RISC-mediated RNA-pairing activities of microRNA-328 is required for maturation-arrest and enhanced survival of blast crisis CML progenitors (2010) (1)
- Favorable Activity of CD19-Targeted Chimeric Antigen Receptor (CD19CAR) T Cell Therapy in Adults with Relapsed/ Refractory (R/R) ALL Including Extramedullary Disease (EMD) and Ph-like Genotype, Using Naive/Memory (Tn/ Mem) Derived T Cells (2022) (1)
- Reply to K. Orendi et al. (2013) (1)
- Human ILC1s target leukemia stem cells and control development of AML (2023) (1)
- Dual Epigenetic Control of CCAAT/Enhancer Binding Protein α (C/EBPα) Expression in Acute Myeloid Leukemia. (2007) (1)
- Inhibition of ROS-Induced Nrf2 Antioxidant Pathway Activation May Explain Synergy between Venetoclax and Hypomethylating Agents Against Acute Myeloid Leukemia (2017) (1)
- Promotes Gene Expression by Disrupting the DNA Binding of the AML1/ETO and HDAC1 Repressor Complex. (2004) (1)
- Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia (2016) (1)
- Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL (2012) (0)
- Autologous and allogeneic hematopoietic stem cell transplantation (HCT) in multiple myeloma (MM): a single institution experience (2000) (0)
- Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents (2016) (0)
- STAT3 Inhibition Enables TLR9-Driven Differentiation of Cbfb/Myh11 acute Myeloid Leukemia Cells to Antigen-Presenting Cell Phenotype In Vivo (2018) (0)
- Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation (2018) (0)
- Immunoliposomal Delivery of Mir-29b By Targeting Tumor Antigen ROR1 Induces Epigenetic Reprograming in Human-ROR1-Expressed Mouse Model of Chronic Lymphocytic Leukemia (2015) (0)
- Abstract 3558: The natural product silvestrol decreases oncogenic FLT3 andmiR-155levels inFLT3-ITD positive Acute Myeloid Leukemia (AML) cells (2010) (0)
- Interleukin-15 Is a Proto-Oncogene In Acute Large Granular Lymphocyte Leukemia (2010) (0)
- Functional Implications of miRNAs in Acute Myeloid Leukemia (AML) by miRNA-mRNA Expression Profiling. (2009) (0)
- A Randomized Open Label Pilot Study of Clostridium Butyricum Miyairi 588 (CBM588) in Recipients of Allogeneic Hematopoietic Cell Transplantation (2021) (0)
- Minimal Residual Disease in Acute Myeloid Leukemia: RT-PCR-Based Studies of Fusion Transcripts (2002) (0)
- Durable Leukemia and HIV Remission without Antiviral Therapy Following an Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) Using a Donor with CCR5-Δ32/Δ32 Homozygosity for an Acute Myeloid Leukemia (AML) Patient (2022) (0)
- Abstract 3249: Targeting the miR29b/Sp1/Dnmt pathway for curative therapy in Mll-PTD/Flt3-ITD acute myeloid leukemia. (2013) (0)
- Biosimulation Using the Cellworks Computational Omics Biology Model (CBM) Identifies Immune Modulation As a Key Pathway for Predicting Azacitidine (AZA) Response in Myelodysplastic Syndromes (MDS) (2021) (0)
- Clinical, Cytogenetic and Immunophenotype Distribution of Adult Acute Lymphoblastic Leukemia Among Latinos — a Report from a Large Single Institution Cohort in Southern California (2018) (0)
- Impact of Donor Activating KIR2DS5 and KIR2DS2 on Outcome of Allogeneic Hematopoietic Cell Transplantation (AlloHCT) in Patients with Acute Myeloid Leukemia (AML) (2016) (0)
- Intracellular Levels of Oblimersen Sodium and Target Downregulation Correlates to Clinical Activity of bcl-2 Antisense in Acute Myeoid Leukemia (AML). (2004) (0)
- Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (2022) (0)
- Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation (2022) (0)
- A validated ultrasensitive hybridization-ELISA assay for synthetic microRNAs in mouse plasma and human leukemia cells and its mouse pharmacokinetics (2008) (0)
- Outcomes of Allogeneic Hematopoietic Cell Transplantation (AlloHCT) in Adults with Philadelphia-like (Ph-like) Acute Lymphoblastic Leukemia (ALL) (2021) (0)
- Targeting SAMHD1 Promotes Anti-Tumor Immunity in Acute Myeloid Leukemia (2022) (0)
- ReSETting PP2A Tumor Suppressor Activity Overcomes BCR/ABL Leukemogenic Potential in Blast Crisis CML. (2005) (0)
- NCCN Acute Myeloid Leukemia , Version 3 . 2017 Clinical Practice Guidelines in Oncology (2017) (0)
- Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results (2012) (0)
- M6A demethylase ALKBH5 selectively promotes tumorigenesis and cancer stem cell self-renewal in acute myeloid leukemia (2020) (0)
- Abstract 2735: An information theoretic approach to investigate AML development using time-series-omics (2022) (0)
- Acute Myeloid Leukemia Cell-Intrinsic PD-1 Functions Promoting Leukemia Development By Recruiting SHP2 (2021) (0)
- with acute myeloid leukemia ) is associated GFI1 ( Growth Factor Independence 1 A variant allele of (2010) (0)
- Potential Targeting Ph+ Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity (2016) (0)
- Single Cell Network Profiling as a Platform to Reveal Leukemia-Specific Signaling Signatures and Sensitivity to Kinase Inhibitor Therapies (2010) (0)
- and DEK coordinately regulate myeloid differentiation α C/EBP (2012) (0)
- Abstract 1570: STAT3 inhibition allows for TLR9-induced reprogramming of acute myeloid leukemia into antigen-presenting cells to generate T-cell mediated immune responses (2021) (0)
- Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL (2022) (0)
- Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML) (2012) (0)
- RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine in acute myeloid leukemia (2012) (0)
- Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy (2022) (0)
- Abstract 1128: Preclinical and pharmacological activities of protein arginine methyltransferase 5(PRMT5) enzyme inhibition in acute myeloid leukemia . (2013) (0)
- PRMT1 Mediated FLT3 Methylation As a Therapeutic Vulnerability in FLT3-ITD+ AML (2018) (0)
- Anti-MiR-126 Therapy for Inv(16) Acute Myeloid Leukemia (2019) (0)
- FLT3-ITD Activates Cytoplasmic Drosha-Dependent Non-Canonical Mechanisms of Mir-155 Biogenesis in Acute Myeloid Leukemia (2019) (0)
- Long Term Outcomes of Patients with Chronic Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation in the Era of Oral Tyrosine Kinase Inhibitors (2022) (0)
- CD84: A Potential Novel Therapeutic Target in the Multiple Myeloma Microenvironment (2019) (0)
- Development and Optimization of Logic Gated Small Interfering RNAs for Operation Inside Mammalian Cells (2020) (0)
- Abstract 3249: Targeting the miR29b/Sp1/Dnmt pathway for curative therapy in Mll-PTD/Flt3-ITD acute myeloid leukemia. (2013) (0)
- Bortezomib-Induced Down-Regulation of KIT Is Mediated by Inhibition of Sp1 and NF-kB in AML1/ETO-Positive Cells. (2006) (0)
- Defective Notch Activation in Mesenchymal Cells Accelerates the Aging of the Bone Marrow Niche and Favor Hematopoietic Malignancies (2018) (0)
- AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML). (2022) (0)
- Allogeneic Stem Cell Transplantation for Patients with Chemo-Refractory or Progressive Aggressive Non-Hodgkin’s Lymphomas. (2008) (0)
- leukemogenesis oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL Identification of novel post-transcriptional targets of the BCR/ABL (2013) (0)
- reveal therapeutic targets in transgenic ERG myeloid leukemia Genome-scale expression and transcription factor binding profiles (2013) (0)
- Abstract 951: Role of the MSC-derived exosomal and endogenous JAK2-SET/PP2A-β-catenin-modulator miR-300 in leukemic stem/progenitor proliferation and survival in CML (2016) (0)
- A Phase 1b Study of IDH Inhibition with Enasidenib and MEK Inhibition with Cobimetinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring IDH2 and RAS Signaling Gene Mutations (2022) (0)
- Superior Therapy Response Predictions for Patients with Myelodysplastic Syndrome (MDS) Using Cellworks Singula™: Mycare-020-02 (2020) (0)
- Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation (2021) (0)
- Importance of FLT3 Mutations and Other Genetic Abnormalities in Normal Karyotype AML. (2008) (0)
- Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia (2022) (0)
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Ph-like ALL (2021) (0)
- The Impact of Hypomethylating Agents and BCL-2 Inhibitor on HLA Expression on THP-1 Cells (2021) (0)
- Outlook for 2017: Acute Leukemias, MDS, and CLL (2016) (0)
- Improved Survival of Patients (Pts) with Acute Graft-Versus-Host Disease (aGVHD) During Recent Years: Impact of Donor and Recipient Characteristics (2013) (0)
- Philadelphia (Ph) Chromosome (BCR-ABL1 fusion) As a Recurrent Genetic Abnormality Among Therapy-Related Acute Leukemia (2016) (0)
- Global Assessment of Promoter Methylation in a Murine Model of Cancer Identifies ID4 as a Putative Novel Tumor Suppressor Gene in Human Leukemia. (2004) (0)
- Disulfide-linked liposomes (2010) (0)
- Role of MLL-Wild Type in hematopoesis and leukemia transformation in MLL-Partial Tandem Duplication mouse models (2014) (0)
- Abstract 3482: METTL3-mediated m6A modification controls splicing factor abundance and contributes to CLL progression (2023) (0)
- Histone Deacetylase Inhibitors (HDACIs), Inhibit Proliferation and Induce Apoptosis of Primary and Metastatic Uveal Melanoma Cell Lines in vitro: A Potential Therapeutic Strategy for Uveal Melanoma (UM) (2003) (0)
- AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions. (2022) (0)
- Long-term survival of patients with therapy-related MDS (tMDS) compared with de novo MDS following allogeneic hematopoietic cell transplantation (alloHCT). (2016) (0)
- Cytokine Gene Polymorphisms Are Associated with Disease Response to Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (2018) (0)
- Biosimulation Using the Cellworks Computational Omics Biology Model (CBM)-Based Assessment of Cytarabine (ARA-C) and Anthracycline Response and Novel Biomarker Response Criteria for the Addition of Etoposide (VP16) in Acute Myeloid Leukemia (AML) (2021) (0)
- Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients 75 Years and Older: Another Age Barrier Crossed? (2023) (0)
- Leveraging IFNγ/CD38 regulation to unmask and target leukemia stem cells in acute myelogenous leukemia (2023) (0)
- Differentiation Scoring (DS) Derived from Cellworks Computational Omics Biology Model (CBM) Predicts Response to Hypomethylating Agents (HMA) and Patient Survival in Myelodysplastic Syndrome (MDS) (2022) (0)
- HDAC8 Disrupts DNA Damage Response By Deacetylation of U2AF1 in Inv(16) Acute Myeloid Leukemia (2022) (0)
- State-Transition Analysis of Time-Sequential Gene Expression Identifies Critical Points That Predict Leukemia Development (2017) (0)
- HDAC8 Regulates Long-Term Hematopoietic Stem Cell Quiescence and Maintenance (2016) (0)
- Pulmonary Arterial Hypertension (PAH) Is Associated with Increased Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation (allo HCT) for Myelofibrosis (2019) (0)
- Characterization of HDACI OSU42 as a Novel Histone Deacetylase Inhibitor in AML Cell Lines. (2006) (0)
- Targeting PRMT9 Suppresses Acute Myeloid Leukemia Maintenance (2021) (0)
- EGFL7 Antagonizes NOTCH Signaling, Stimulates Blast Proliferation and Confers Poor Prognosis in Cytogenetically-Normal Acute Myeloid Leukemia (CN-AML) (2016) (0)
- Abstract CT-06: The combination of bortezomib (BOR) and decitabine (DEC): A phase I trial in patients (pts) with acute myeloid leukemia (AML) targeting FLT3 expression (2012) (0)
- Myeloid cell-targeted miR-146a mimic alleviates NF-κB-driven cytokine storm without interfering with CD19-specific CAR T cell activity against B cell lymphoma (2019) (0)
- Transcriptome dynamics describe and predict state transition from health to leukemia (2017) (0)
- Abstract 3454: Bcl-xL anti-apoptotic network is dispensable for emergence and maintenance of CML but required for disease progression, and represents an alternative target for halting survival of blast crisis CML progenitors. (2013) (0)
- The 14q32.31 DLK1-DIO3 MIR300 tumor suppressor promotes leukemogenesis by inducing cancer stem cell quiescence and inhibiting NK cell anti-cancer immunity (2019) (0)
- Abstract 2858: A novel mouse model for cutaneous T-cell lymphoma reveals a role for IL-15 and activity of a new oral HDAC inhibitor (2011) (0)
- The Effect of Mycophenolate Mofetil Dose per Kilogram on Outcomes of Haploidentical Donor Peripheral Blood Stem Cell Transplant with Post-Transplant Cyclophosphamide (2023) (0)
- Micro-RNA and Gene Expression In CLL: Network Analysis Elucidating the Complex Role of the NF-κB Signaling Pathway In Disease. (2010) (0)
- PF256 RATIFY: PROGNOSTIC IMPACT OF FLT3 TYROSINE KINASE DOMAIN (TKD) AND NPM1 MUTATION STATUS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) TREATED WITH MIDOSTAURIN + STANDARD CHEMOTHERAPY (2019) (0)
- Molecular Landscaping of AML: Are we relearning the Past or Informing the Future? (2014) (0)
- New Drug May Be a Game Changer for Chronic Myeloid Leukemia Patients (2018) (0)
- Activation of a Mir-181-Targeting HOXA-PBX3 Homeobox Gene Signature Is Associated with Adverse Prognosis of Cytogenetically Abnormal Acute Myeloid Leukemia (2011) (0)
- Improving the molecular risk classification for younger (<60 years) de novo cytogenetically normal acute myeloid leukemia (CN AML) patients (pts). (2009) (0)
- Venetoclax Synergizes with the RNA-Directed Nucleoside Analog 8-Chloro-Adenosine in Acute Myeloid Leukemia in Vitro and In Vivo (2020) (0)
- Homoharringtonine Exhibits Anti-Tumor Effect in T-Cell Acute Lymphoblastic Leukemia By Targeting Notch1/Myc Pathway (2022) (0)
- Fludarabine and Melphalan (FM) with Post-Transplant Cyclophosphamide (PTCy) for Peripheral Blood Stem Cell (PBSC) Allogeneic Hematopoietic Cell Transplant (HCT) in Patients with Hematologic Malignancies (2023) (0)
- t(8;21) Acute Myeloid Leukemia (AML) Differs from inv(16) AML in Pretreatment Characteristics, Outcome and Prognostic Factors Predicting Outcome: A Cancer and Leukemia Group B (CALGB) Study. (2004) (0)
- COVID and Cancer: A Complete 3D Advanced Radiological CT-Based Analysis to Predict the Outcome (2023) (0)
- Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance) (2021) (0)
- MODELING and Targeting ERG -INDUCED Acute MYELOID LEUKEMIA (AML). (2009) (0)
- Erratum: Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma (Blood (2018) 131:7 (741-745) DOI: 10.1182/blood-2017-09-807263) (2018) (0)
- OM301, a Synthetic Polypeptide Containing the p53TA (Transactivation) Domain, Impairs Mitochondrial Activity and Survival of Myeloma Cells (2021) (0)
- Phosphorylation stabilized TET1 acts as an oncoprotein and therapeutic target in B cell acute lymphoblastic leukemia (2022) (0)
- Acute Lymphoblastic Leukemia (ALL) as a Second Primary Malignancy (SPM) After Multiple Myeloma (MM): Secondary Clonally Related Neoplasm or Therapy-Related Leukemia? (2017) (0)
- Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD). (2006) (0)
- Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation with Measurable Residual Disease and the Impact of Conditioning Regimen and Graft-Versus-Host Disease Prophylaxis Intensity: A Single Center Retrospective Analysis (2023) (0)
- STAT3 SIGNALING AS A CHECKPOINT FOR TLR9-DRIVEN EPIGENETIC REPROGRAMMING OF ACUTE MYELOID LEUKEMIA INTO ANTIGEN-PRESENTING CELLS (2022) (0)
- PC-12 Bone marrow microenvironment-induced miR-300 expression impairs natural killer cell proliferation and anti-tumor activity (2019) (0)
- CD84: A Potential Novel Therapeutic Target in Multiple Myeloma (2018) (0)
- Evaluation of Rabbit Antithymocyte Globulin (rATG) Dose-Intensity in Patients Undergoing Allogeneic Stem Cell Transplantation (ASCT) Following Reduced Intensity Conditioning (RIC) with Fludarabine, Busulfan and rATG (FBA) (2009) (0)
- BCR/ABL Post-Translationally Enhances hnRNP E2 Expression and Translation-Inhibitory Function through the Activation of ERK1/2 Mitogen-Activated Protein Kinases. (2005) (0)
- Abstract 1307: Heritable polymorphism predisposes to high expression ofBAALCin cytogenetically normal acute myeloid leukemia (CN-AML) (2012) (0)
- Genomics of primary chemoresistance and remission induction failure in pediatric and adult acute myeloid leukemia (2016) (0)
- HDAC Inhibitors and Cardiac Safety (2007) (0)
- Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine. (2009) (0)
- Biosimulation Using the Cellworks Computational Omics Biology Model (CBM) Predicted Novel Biomarkers for Hyper-CVAD (CVAD) Treatment Response and Combination of Rituximab and Cladribine (RC) in CVAD Resistant Cases of Mantle Cell Lymphoma (MCL) (2021) (0)
- Downregulation of Mir-142 Promotes Leukemia Growth in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): A Possible Novel Therapeutic Target? (2018) (0)
- Ramasamy myeloid leukemia in acute microRNA-181 a upregulates expression of the antileukemic-p 30 protein α Lenalidomide-mediated enhanced translation of C / EBP (2012) (0)
- Myeloablative Vs Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation in Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (2022) (0)
- Reply to “Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases”. Haematologica 2014;99(2):e20–21. (2014) (0)
- Abstract 3849: The partial tandem duplication of Mll (Mll PTD) is a gain-of-function in the absence of Mll wildtype (Mll WT) in adult mouse hematopoiesis. (2013) (0)
- SARS-CoV-2 infection in patients with β-thalassemia : Experience from Lebanon (2021) (0)
- Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis (2022) (0)
- Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia (2015) (0)
- The Histone Deacetylase Inhibitor Depsipeptide Mediates Distinct Patterns of Histone Acetylation in Cells Overexpressing Bcl-2. (2004) (0)
- Report of four acute myeloid leukemia patients with sustained complete remission with less frequent administration of decitabine and venetoclax (2023) (0)
- Abstract 5065: Predicting response to chemotherapy in a mouse model of acute myeloid leukemia (2022) (0)
- 8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth and Synergizes with the BCL-2 Inhibitor Venetoclax (ABT-199) (2016) (0)
- Improved non-relapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced intensity conditioning allogeneic transplantation for hematologic malignancies (2014) (0)
- Imatinib Mesylate-Induced Complete Cytogenetic Response in Acute Myeloid Leukemia with t(5;12)(q33;p13). (2006) (0)
- Publisher Correction: ILC1s control leukemia stem cell fate and limit development of AML (2022) (0)
- Phosphorylation Of GSK3β Is Associated With Inferior Survival In Acute Myeloid Leukemia and Is An Indicator Of AKT Activation In AML Blasts and Bone Marrow Mesenchymal Stem Cells (2013) (0)
- Microrna-142 Deficiency Promotes Chronic Myeloid Leukemia (CML) Transformation from Chronic Phase (CP) to Blast Crisis (BC) (2020) (0)
- METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL. (2023) (0)
- karyopherin inhibitor KPT-330 in Ph Preclinical and clinical efficacy of XPO 1 / CRM 1 inhibition by the (2013) (0)
- ong-term Outcome of Hodgkin Disease Patients ollowing High-Dose Busulfan, Etoposide, yclophosphamide, and Autologous tem Cell Transplantation (2006) (0)
- Updates on Acute Myeloid Leukemia Management in older patients (2021) (0)
- Minimal Residual Disease in Acute Myeloid Leukemia (2003) (0)
- Hodgkin's disease Second autologous stem cell transplant for multiply relapsed Hodgkin's disease (2002) (0)
- Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (2022) (0)
- Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations (2022) (0)
- Aberrant Epigenetic Suppression of the Ptprot Gene Encoding a Protein Tyrosine Phosphatase Targeting KIT in Acute Myeloid Leukemia (2012) (0)
- Therapy Biosimulation Using the Cellworks Computational Omics Biology Model (CBM) Is Predictive of Individual Acute Myeloid Leukemia (AML) Patient Probability of Clinical Response (CR) and Overall Survival (OS): Mycare-023 (2021) (0)
- Abstract 3083: The genetic landscape of Ph-like acute lymphoblastic leukemia (2014) (0)
- Depsipeptide (DP), Histone Deacetylase Inhibitor (HDACI), Inhibits Migration of Primary and Metastatic Uveal Melanoma (UM) Cells by Down-regulation of Matrix Metalloproteinase (MMP) 2 and 9 Gene Expression (2003) (0)
- Targeting PRMT9 Elicits Cgas-Mediated Anti-Leukemia Immunity (2022) (0)
- Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors. (2009) (0)
- Consolidation with Allogeneic Hematopoietic Cell Transplant Improved Survival Outcomes of Adults with Relapsed / Refractory Acute Lymphoblastic Leukemia Following Response to Memory-Enriched CD19CAR T Cells (2022) (0)
- Abstract #5447: In vitro-in vivo pharmacodynamic analysis of GTI-2040 combined with Ara-C in acute myeloid leukemia (2009) (0)
- Caserta E, Chea J, Minnix M, et al. Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. Blood. 2018;131(7):741-745. (2018) (0)
- MiR-3151, a Novel MicroRNA Embedded in BAALC, Is Only Weakly Co-Expressed with Its Host Gene and Independently Impacts on the Clinical Outcome of Older Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (2011) (0)
- Gene and microRNA (miRNA) Expression Signatures and Prognostic Significance of CEBPA Mutations in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML) with High-Risk Molecular Features: A Cancer and Leukemia Group B (CALGB) Study. (2007) (0)
- Abstract 4736: Bone marrow microenvironment-induced miR-300 expression impairs natural killer cell proliferation and antitumor activity (2018) (0)
- MLL-PTD Causes Hypomorph Condition of CBF Complex (RUNX1/CBFβ) and Predisposes the Abnormal Hematopoietic Stem and Progenitor Cells (HSPCs) to Clonal Expansion (2011) (0)
- Multiplexed Digital Quantification of mRNA Abundance: a Highly Reproducible, PCR–independent Assessment of BAALC , ERG , and MN1 mRNA Levels in Acute Myeloid Leukemia (AML) Bone Marrow (BM) and Peripheral Blood (PB) Samples. (2009) (0)
- MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis (2018) (0)
- Pulmonary Engraftment Syndrome: A Unique Complication of Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis (2022) (0)
- Multi-Antigen Primed T Cells Promote Apoptosis of Acute Myeloid Leukemia (AML) (2021) (0)
- Poster: AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML) (2022) (0)
- Outcomes of MDS Patients with and without Spliceosome Mutations Undergoing Allogeneic Hematopoietic Cell Transplantation (2023) (0)
- Table of Contents, Editor's Choice, Highlights (2018) (0)
- Repurposing Nelarabine to Induce Differentiation of Acute Myeloid Leukemia (2020) (0)
- Patterns and Outcomes of Relapse Treated With Radiotherapy Following Total Marrow and Lymphoid Irradiation in High-Risk and/or Relapsed/Refractory Acute Leukemia. (2021) (0)
- Frequent Early Geriatric Complications after Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Adults Impairs Disability-Free Survival (DiFS) (2022) (0)
- CD84 Is a Therapeutically Targetable Driver of Leukemogenesis Via Disruption of Energy Supply in Acute Myeloid Leukemia (2022) (0)
- Abstract 1111: SyntheticmicroRNA (miR)-181ananoparticles (NP) target RAS and sensitize cells to daunorubicin (DNR) in acute myeloid leukemia (AML) (2012) (0)
- Hemorrhagic Cystitis in Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Post Transplant Cyclophosphamide As GvHD Prophylaxis (2020) (0)
- Translational Research From the Tropical Forest: Silvestrol, a Natural Product From the Plant Aglaia Foveolata inhibits the Expression of Tyrosine Kinases and Shows a Significant In Vivo Activity in Acute Myeloid Leukemia (AML) (2011) (0)
- Targeting MiR-126 Blocks Progression of Myelodysplastic Syndrome and Transformation into Acute Myeloid Leukemia (2019) (0)
- PNC¯27 Targeting Plasma Membrane HDM2: A Potentially Novel Therapeutic Approach for Acute Myeloid Leukemia (AML) (2017) (0)
- Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide (2022) (0)
- MicroRNA-142 Is an Essential Negative Regulator of B Cell Maturation and Malignant Transformation (2019) (0)
- TET2-Mediated mRNA and DNA Oxidation in Leukemia Homing and Immune Evasion (2022) (0)
- Resection of Uninvolved Adjacent Organs Can Be Part of Surgery for Retroperitoneal Soft Tissue Sarcoma (2009) (0)
- AML-491 Real World Practice of FLAG-Idarubicin-Venetoclax in Relapsed Refractory AML: A Single Center Experience. (2022) (0)
- Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study (2023) (0)
- A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2’-O-Methylphosphorothioate Mir-29b (2013) (0)
- The impact of SARS-CoV2 vaccines on the incidence of graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective study (2023) (0)
- Spred1 Insufficiency in the Hematopoietic and/or Vascular Compartments of the Bone Marrow (BM) Niche Promotes Aggressive Leukemogenesis in Chronic Myelogenous Leukemia (CML) (2019) (0)
- Requirement of the E2F3 Transcription Factor for BCR/ABL Leukemogenesis. (2007) (0)
- Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML) (2022) (0)
- Leukemia Group B study myeloid leukemia and MLL partial tandem duplication: a Cancer and Long-term disease-free survivors with cytogenetically normal acute (2013) (0)
- Decitabine priming enhances the anti-leukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia Running head: Decitabine and XPO1 inhibition in AML (2015) (0)
- Distinguishing Antiphospholipid Antibodies from an Acquired Factor Inhibitor: A Novel Laboratory Approach. (2005) (0)
- The BCR-ABL1-Regulated hnRNP A1, hnRNP E2, and hnRNP K Are Differentially Expressed Between CD34+ and CD34+/CD38- Ph+ Cells, and After Blastic Transformation of CML. (2010) (0)
- A Pilot Phase II Trial of Combining Extracorporeal Photopheresis (ECP) and Low Dose IL-2 for Treatment of Sclerodermatous Steroid Refractory Chronic Graft-Versus-Host Disease (cGvHD) (2019) (0)
- Targeted Delivery of miR-146a Mimic Oligonucleotides as a Potential Therapeutic Approach to Modulate NF-kB Signaling in Myeloid Leukemia and Myeloproliferative Diseases (2018) (0)
- Superior therapy response predictions for patients with acute myeloid leukemia (AML) using Cellworks Singula: MyCare-009-01. (2020) (0)
- Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions (2022) (0)
- A phase I study of GTI-2040 (G), an antisense to ribonucleotide reductase (RNR), in combination with high-dose AraC (HiDAC) in acute myeloid leukemia (AML). (2006) (0)
- PF260 PROGNOSTIC AND PREDICTIVE IMPACT OF NPM1/FLT3-ITD GENOTYPES AS DEFINED BY 2017 EUROPEAN LEUKEMIANET RISK CATEGORIZATION FROM AML PATIENTS TREATED WITHIN THE INTERNATIONAL RATIFY STUDY (2019) (0)
- The Impact of Letermovir (LTV) Prophylaxis on Early Cytomegalovirus Infection (CMVi) and Outcomes in the Adult Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients with High-Risk Donor Type (2021) (0)
- Effect of Vancomycin-Resistance Enterococci Colonization Status Prior to Allogeneic Hematopoietic Cell Transplantation on Transplant Outcomes: A Single Center Retrospective Experience (2018) (0)
- The Tumor Suppressor Gene SLC5A8 Is Selectively Silenced in MLL Partial Tandem Duplication-Positive Acute Myeloid Leukemia with Normal Cytogenetics. (2006) (0)
- Therapy-Related Myelodysplasia: Somatic Mutations and Allogeneic Hematopoietic Cell Transplantation Outcomes (2017) (0)
- Abstract 3857: Targeting HDAC1 in a novel model of cutaneous T-cell lymphoma. (2013) (0)
- Simultaneous metabolic labeling of cells with multiple amino acids: Localization and dynamics of histone acetylation and methylation (2007) (0)
- Decitabine Or 5-Azacitidine Pre-Treatment Does Not Compromise The Novel Fc-Engineered Antibody Mab 33.1-Mediated ADCC Against Primary AML Blasts - A Rationale For Combination Therapy (2013) (0)
- Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience (2021) (0)
- Application of NSG in Newly Diagnosed AML (2017) (0)
- MiR-300 Acts As a Tumor Supressor in Ph+ Progenitors By Modulating the JAK2-SET/PP2A/β-Catenin Interplay (2014) (0)
- Nuclear Export (Karyopherin) Inhibitors: A Novel Therapeutic Strategy for Treating Blast Crisis Chronic Myelogenous Leukemia (CML) and Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Through Interference with hnRNP Nucleocytoplasmic Shuttling and Rescue of Protein Phosphatase 2A (PP2A (2011) (0)
- Antileukemic Activity of 8-Chloro-Adenosine (8-Cl-Ado) Is Mediated By Mir-155 Degradation and ErbB3 Binding Protein (Ebp1)-Dependent p53 Activation: A Novel Therapeutic Approach for FLT3-ITD Acute Myeloid Leukemia (AML) (2018) (0)
- Erratum: Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia (Cancer (2013) 119 (90-8)) (2014) (0)
- Targeted Delivery of CpG-Mir-146a Mimic Oligonucleotides As a Therapeutic Strategy to Reduce NF-Κb-Mediated Pathogenic Inflammation and Myeloid Leukemia Progression (2018) (0)
- Time Sequential Transcriptome Analysis Identifies Mir-126 As an Early Biomarker for Inv(16) Acute Myeloid Leukemia (AML) Disease Progression (2016) (0)
- 795 STAT3 signaling as a checkpoint for TLR9-driven epigenetic reprogramming of acute myeloid leukemia into antigen-presenting cells (2022) (0)
- Targeting Mir-155 via The NEDD8-Activating Enzyme Inhibitor MLN4924: A Novel Therapeutic Approach For Acute Myeloid Leukemia (AML) (2013) (0)
- Targeting Leukemic Stem Cells in Acute Myeloid Leukemia Using a CpG-Linked Anti-Mir-126 Oligonucleotide (2022) (0)
- Outcome Prediction By the New 2022 European Leukemia Net (ELN) Genetic-Risk Classification for Adult Patients (Pts) with Acute Myeloid Leukemia (AML): An Alliance Study (2022) (0)
- Detection of Unique ALLÃ(cid:141) (MLL) Fusion Transcripts in Normal Human Bone Marrow and Blood: Distinct Origin of Normal versus Leukemic ALLÃ(cid:141) Fusion Transcripts1 (2006) (0)
- Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis (2022) (0)
- Book Review Innovative Leukemia and Lymphoma Therapy (Basic and Clinical Oncology. 35.) Edited by Gertjan J.L. Kaspers, Bertrand Coiffier, Michael C. Heinrich, and Elihu Estey. 598 pp., illustrated. New York, Informa Healthcare, 2008. $279.95. 978-0-8493-5083-2 (2009) (0)
- Abstract 979: microRNA-mediated leukemia-initiating cell activity (2014) (0)
- Aging, Clonal Hematopoiesis and Therapy-related Myeloid Neoplasms: Personalizing the Risk of Chemotherapy Treatments (2018) (0)
- A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502. (2012) (0)
- Association of abnormal cytogenetics at date of morphologic complete remission (CR) with overall (OS), disease-free survival (DFS) and higher relapse rate in acute myeloid leukemia (AML): Results from Cancer and Leukemia Group B (CALGB) 8461. (2004) (0)
- In Vivo Quantification of Active Decitabine-Triphosphate Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (2012) (0)
- Activated Natural Killer Cells Are Associated with Poor Clinical Prognosis in High-Risk B- and T- Cell Acute Lymphoblastic Leukemia (2020) (0)
- Abstract 1134: The tumor suppressor activity of miR-300 is detrimental for leukemia development but required for leukemia stem cell maintenance (2018) (0)
- A Mathematical Model of Mirna Dynamics Predicts State Transition and Identifies Mirna-126 as an Onco-Mir Promoting Acute Myeloid Leukemia Driven by CBFB-MYH11 (2018) (0)
- Total Marrow and Lymphoid Irradiation to 20 Gy Combined With Post-Transplant Cyclophosphamide Graft vs. Host Disease (GvHD) Prophylaxis is Associated With Low Non-Relapse Mortality Rates and Favorable GvHD-Free/Relapse-Free Survival in AML. (2021) (0)
- Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation (2022) (0)
- In Vitro and In Vivo Evidence That TSC-22 Is a Putative Tumor Suppressor Gene in Primary Murine and Human Leukemia. (2006) (0)
- Differential Clinical Impact Of Gene Mutations and Their Combinations In Primary Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (2013) (0)
- CT-505 Fractionated Total Body Irradiation and Fludarabine Based Conditioning Regimen With Post-Transplant Cyclophosphamide (PTCy) for Mismatched Related and Unrelated Donors HCT for Acute Leukemia and MDS. (2022) (0)
- Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL) (2022) (0)
- Infection 1430 1 1 a U G U S T 2 0 1 1 I V O L U M E 1 1 8 , N U M B E R 6 Blood (0)
- (Mll-PTD) hematopoietic stem/progenitor cells bias, and myeloid differentiation in Mll partial tandem duplication Stress hematopoiesis reveals abnormal control of self-renewal, lineage (2013) (0)
- TET2 deficiency promotes MDS-associated leukemogenesis (2022) (0)
- Dose-dependent activity of decitabine in Kasumi-1 cells (2011) (0)
- Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML) (2011) (0)
- Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity (2022) (0)
- Enrichment-based DNA methylation analysis using next-generation sequencing: sample exclusion, estimating changes in global methylation, and the contribution of replicate lanes (2012) (0)
- Acute Myeloid Leukemia Interplay of RUNX 1 / MTG 8 and DNA Methyltransferase 1 in Updated (2005) (0)
- A Multivariate Clinical and Economic Model for Predicting Risk-Based Costs of Care for Acute Leukemia (AL) Patients (Pts) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) (2016) (0)
- Poster: AML-491 Real World Practice of FLAG-Idarubicin-Venetoclax in Relapsed Refractory AML: A Single Center Experience (2022) (0)
- 5-Azacytidine, a possible new inhibitor of ribonucleotide reductase (R2), and its combined biological effect with GTI 2040 in chronic and acute myeloid leukemia cells (2008) (0)
- Real World Experience of Letermovir (LTV) Prophylaxis (Px) for the Prevention of Cytomegalovirus Infection (CMVi) in the Adult CMV Seropositive Recipients (R+) of Allogeneic Hematopoietic Cell Transplantation (HCT) Patients (pts). (2019) (0)
- Assessment of Cellworks Omics Biosimulation Therapy Response Predictions for Patients with Acute Myeloid Leukemia (AML) Using Cellworks Singula™: Mycare-020-01 (2020) (0)
- Proteasome inhibition enhances myeloma oncolytic reovirus therapy by suppressing monocytic anti-viral immune responses (2022) (0)
- Adverse Impact of Renal Impairment on Outcome of Patients Undergoing Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Guido I. Marcucci?
Guido I. Marcucci is affiliated with the following schools:
